GRCE
Grace Therapeutics, Inc. NASDAQ$2.36
Mkt Cap $36.5M
52w Low $1.79
16.8% of range
52w High $5.18
50d MA $3.94
200d MA $3.44
P/E (TTM)
-3.0x
EV/EBITDA
-0.3x
P/B
0.4x
Debt/Equity
0.0x
ROE
-11.9%
P/FCF
-1.8x
RSI (14)
—
ATR (14)
—
Beta
0.69
50d MA
$3.94
200d MA
$3.44
Avg Volume
701.3K
About
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-fo…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AMC | -0.09 | -0.14 | -55.6% | 3.53 | +0.8% | +2.3% | +11.6% | +11.9% | +10.5% | +9.9% | +25.2% | — |
| Nov 13, 2025 | AMC | -0.12 | -0.15 | -25.0% | 3.10 | -0.3% | -1.3% | -3.2% | +1.9% | +0.6% | +1.3% | +4.5% | — |
| Aug 12, 2025 | AMC | -0.22 | -0.21 | +4.5% | 3.21 | -0.6% | +2.2% | -4.0% | +1.6% | +0.6% | +2.5% | +0.3% | — |
| Jun 23, 2025 | AMC | -0.20 | -0.21 | -5.0% | 2.93 | -0.7% | +2.4% | +1.0% | +0.3% | +1.4% | +1.4% | +14.3% | — |
| Feb 13, 2025 | AMC | -0.24 | -0.26 | -8.3% | 3.48 | -2.6% | -0.9% | -1.7% | -4.0% | -2.6% | -5.5% | -34.2% | — |
| Nov 13, 2024 | AMC | -0.33 | -0.33 | +0.0% | 3.05 | +1.3% | +8.5% | +2.0% | +3.6% | +3.3% | +7.5% | +17.4% | — |
| Aug 9, 2024 | AMC | -0.28 | -0.24 | +14.3% | — | — | — | — | — | — | — | — | — |
| Jun 21, 2024 | AMC | -0.35 | -0.18 | +48.6% | — | — | — | — | — | — | — | — | — |
| Feb 12, 2024 | AMC | -0.23 | -0.24 | -4.4% | — | — | — | — | — | — | — | — | — |
| Nov 13, 2023 | AMC | -0.26 | -0.32 | -23.0% | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | TD Cowen | Maintains | Buy → Buy | — | $2.35 | $2.22 | -5.5% | -2.1% | -8.1% | -10.6% | -10.6% | -4.7% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.45 | $3.47 | +0.6% | -0.9% | -3.2% | -1.7% | -4.6% | -11.3% |
Recent Filings
8-K · 8.01
!! High
Grace Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Grace Therapeutics updated its corporate presentation, signaling potential strategic messaging or investor communication changes that may reflect new business developments or positioning.
Apr 27
8-K · 8.01
!! High
Grace Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Grace Therapeutics' GTx-104 received a Complete Response Letter from the FDA, meaning the company must address deficiencies before resubmission, delaying commercialization of its aneurysmal subarachnoid hemorrhage treatment.
Apr 23
8-K
Grace Therapeutics, Inc. -- 8-K Filing
Grace Therapeutics reported Q4 2025 results highlighting progress on GTx-104, its late-stage injectable nimodipine candidate for aneurysmal subarachnoid hemorrhage treatment.
Feb 12
Data updated apr 25, 2026 12:15pm
· Source: massive.com